Detalles de la búsqueda
1.
Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.
J Natl Compr Canc Netw
; 22(2D)2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38866043
2.
Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers.
Ann Surg Oncol
; 30(3): 1312-1326, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36335273
3.
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.
J Natl Compr Canc Netw
; 21(10): 1000-1010, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37856201
4.
Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations.
BJOG
; 130(12): 1437-1450, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37132126
5.
TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.
Int J Gynecol Cancer
; 33(6): 982-987, 2023 06 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37045546
6.
Characterization of splice-altering mutations in inherited predisposition to cancer.
Proc Natl Acad Sci U S A
; 116(52): 26798-26807, 2019 Dec 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-31843900
7.
Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research.
Carcinogenesis
; 42(6): 785-793, 2021 06 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-34037709
8.
Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
Gynecol Oncol
; 163(1): 130-133, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34452747
9.
Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
Gynecol Oncol
; 160(3): 786-792, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33375991
10.
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 19(1): 77-102, 2021 01 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33406487
11.
Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
Gynecol Oncol
; 157(2): 514-520, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32199636
12.
Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years.
Gynecol Oncol
; 159(1): 214-220, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32709535
13.
Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
Gynecol Oncol
; 156(3): 517-522, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31883735
14.
Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
Gynecol Oncol
; 156(2): 407-414, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31839337
15.
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
J Natl Compr Canc Netw
; 18(4): 380-391, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32259785
16.
An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.
Int J Gynecol Pathol
; 39(3): 261-269, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31033800
17.
MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing.
BMC Cancer
; 19(1): 648, 2019 Jul 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31266460
18.
Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
Gynecol Oncol
; 153(1): 192-200, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30661763
19.
Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.
Gynecol Oncol
; 153(2): 217-222, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30803719
20.
ASO Visual Abstract: Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers.
Ann Surg Oncol
; 30(3): 1329-1330, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36414905